These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 22442719)

  • 41. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression.
    Zhu J; Yang DR; Sun Y; Qiu X; Chang HC; Li G; Shan Y; Chang C
    Mol Cancer Ther; 2015 Jun; 14(6):1445-53. PubMed ID: 25833838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression analysis of putative stem cell markers in human benign and malignant prostate.
    Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
    Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma.
    Huang D; Wang X; Zhuang C; Shi W; Liu M; Tu Q; Zhang D; Hu L
    Oncol Rep; 2016 Feb; 35(2):1083-90. PubMed ID: 26718325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
    Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
    Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
    Rizzo S; Hersey JM; Mellor P; Dai W; Santos-Silva A; Liber D; Luk L; Titley I; Carden CP; Box G; Hudson DL; Kaye SB; Brown R
    Mol Cancer Ther; 2011 Feb; 10(2):325-35. PubMed ID: 21216927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
    Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ
    Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
    Sander S; Bullinger L; Klapproth K; Fiedler K; Kestler HA; Barth TF; Möller P; Stilgenbauer S; Pollack JR; Wirth T
    Blood; 2008 Nov; 112(10):4202-12. PubMed ID: 18713946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
    Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
    Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
    Shin YJ; Kim JH
    PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
    Qiu X; Wang W; Li B; Cheng B; Lin K; Bai J; Li H; Yang G
    BMC Cancer; 2019 Jan; 19(1):27. PubMed ID: 30621625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long noncoding RNA FOXC2-AS1 facilitates the proliferation and progression of prostate cancer via targeting miR-1253/EZH2.
    Chen Y; Gu M; Liu C; Wan X; Shi Q; Chen Q; Wang Z
    Gene; 2019 Feb; 686():37-42. PubMed ID: 30389560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
    Xia H; Ooi LL; Hui KM
    PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization.
    Park JM; Lee JE; Park CM; Kim JH
    Mol Cells; 2019 Jan; 42(1):17-27. PubMed ID: 30622230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
    Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.